Cost-Effectiveness of Extended Adjuvant Rituximab for US Patients Aged 65–70 Years with Follicular Lymphoma in Second Remission

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

Lindsay M. Morton, Sophia Wang, Susan S. Devesa et al. · Blood · 2005 · 1.7K citations · Full text

Medicine, Oncology, Cancer Epidemiology +13

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Marinus H. J. van Oers, Richard Klasa, Robert Marcus et al. · Blood · 2006 · 593 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Cancer Surveillance Series: Non-Hodgkin's Lymphoma Incidence by Histologic Subtype in the United States From 1978 Through 1995

Frank D. Groves, Martha S. Linet, Lois B. Travis et al. · JNCI Journal of the National Cancer Institute · 2000 · 527 citations

Medicine, Oncology, Pathology +17

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling et al. · Blood · 2006 · 465 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

United States life tables, 2003.

Elizabeth Arias · PubMed · 2006 · 378 citations

Social Sciences, Demography, Epidemiology +16